Primary central nervous system lymphoma (PCNSL)
Cooperative Study Group
PD Dr. Elisabeth Schorb
Principal Investigator
Sekretariat: Dr.rer.nat. Peggy Engelhard
+49 761 270 35360
kontakt.studiengruppe.zns-nhl@uniklinik-freiburg.de
peggy.engelhard@uniklinik-freiburg.de
Universitätsklinikum Freiburg
Klinik für Innere Medizin I
Hugstetter Straße 55
D-79106 Freiburg
Scientific focus
CNS lymphomas are rare, often aggressive diseases with heterogeneous outcomes that are often inferior to those of systemic lymphomas. Due to the different CNS localizations, patients may present with multiple neurological deficits and/or non-specific symptoms. In addition, the CNS localizations represent an additional obstacle regarding the choice of antineoplastic agents and their intracerebral efficacy.
The German Cooperative Primary CNS Lymphoma (PCNSL) Study Group has conducted several clinical trials to address these and other important issues in the treatment of PCNSL, whether in newly diagnosed, relapsed or elderly PCNSL patients.
Founded in 1998 and based in Freiburg and Stuttgart, Germany, the group has a proven track record in each of these indications. Starting with early pilot studies investigating different immuno-chemotherapy protocols, these have been refined and validated in large international multicenter trials and published in high-impact journals.
Recently, the German Cooperative PCNSL Study Group completed two of the world's largest randomized trials in PNCSL: the randomized phase III MATRixX/IELSG43 trial in 330 patients from 35 centers comparing high-dose consolidation chemotherapy followed by autologous stem cell transplantation (HCT-ASCT) with conventional doses of chemotherapy, and the phase II MARTA trial in 54 patients from 15 German centers evaluating age-adjusted HCT-ASCT in an elderly cohort of PCNSL patients.
MATriX: (https://doi.org/10.1182/blood-2022-171733 )
MARTA: https://doi.org/10.1016/S2352-3026(23)00371-X
Following these studies, two additional prospective investigator-initiated trials were designed to further refine treatment strategies in individual PCNSL patients with different needs in terms of age, performance status and comorbidities. The randomized phase III OptiMATe trial aims to refine the sequence and intensity of treatment by comparing the current standard of care with a shortened version of it. This trial is being conducted on a multinational basis in 4 different countries (Germany, UK, Austria, Italy). The phase III PRIMA-CNS trial is again focused on older, frailer PCNSL patients, who make up the majority of this population and for whom eligibility for intensive treatment strategies is often a challenge. This trial will compare the current standard of care (immuno-chemotherapy followed by maintenance therapy) with the regimen tested in the MARTA trial.
All PCNSL trials are supported by translational research programs (AG Scherer), the primary goal of which is to identify molecular biomarkers that predict clinical outcome and to understand the underlying biology of treatment response and failure in PCNSL patients.
In addition to these large studies in PCNSL, the group is investigating clinical subprojects on various aspects of the clinical management of primary and secondary CNS lymphomas to better understand the nature and dynamics of these diseases.
Ongoing clinical trials
OptiMATe Optimizing MATRix as remission induction in PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial
https://doi.org/10.1186/s12885-022-09723-w
PRIMA-CNS: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly CNS lymphoma patients - a randomized phase III trial
Trials- recruiting
OptiMATe Optimizing MATRix as remission induction in PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial
More Information
OptiMATe mit aktualisierter Synopse
Contact:
- Coordinating Principal Investigator: Prof. Dr. med. Gerald Illerhaus (Stuttgart)
- Deputy Principal Investigator: PD Dr. med. Elisabeth Schorb (Freiburg)
- Project management: Elvira Burger (Freiburg)
VENOBI CNS- Chemotherapy free treatment with venetoclax and obinutuzumab for relapsed / refractory primary CNS lymphoma patients (VENOBI-CNS study) - A phase IB study to assess the pharmacokinetics in the cerebrospinal fluid-
More Information
Contact:
- Coordinating Principal Investigator: Prof. Dr. med. Gerald Illerhaus (Stuttgart)
- Deputy Principal Investigator: PD Dr. med. Elisabeth Schorb (Freiburg)
- Project management: Elvira Burger (Freiburg)
Trials in follow up
MATRix/IELSG43- High dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial
Recruitment was finished August 2019
More Information
Contact:
- Coordinating Principal Investigator: Prof. Dr. med. Gerald Illerhaus (Stuttgart)
- Deputy Principal Investigator: PD Dr. med. Elisabeth Schorb (Freiburg)
- Project management: Elvira Burger (Freiburg)
MARTA - Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
Recruitment was finished September 2020
More Information
Contact:
- Coordinating Principal Investigator: Prof. Dr. med. Gerald Illerhaus (Stuttgart)
- Deputy Principal Investigator: PD Dr. med. Elisabeth Schorb (Freiburg)
- Project management: Elvira Burger (Freiburg)
Planned Trials
PRIMA-CNS - Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly CNS lymphoma patients - a randomized phase III trial
Start of recruitment: 4th quarter 2022
More Information
Contact:
- Coordinating Principal Investigator: Prof. Dr. med. Gerald Illerhaus (Stuttgart)
- Deputy Principal Investigator: PD Dr. med. Elisabeth Schorb (Freiburg)
- Project management: Elvira Burger (Freiburg)
PD Dr. med. Elisabeth Schorb
+49 761 270 35360
+49 761 270 73570
Dr. med. Lisa Isbell
Medical Project Coordinator
+49 761 270 18760
+49 761 270 34010 (Pforte)
Dr. med. Eliza Lauer
Medical Project Coordinator
+49 761 270 18760
+49 761 270 34010 (Pforte)
András Orban
Clinician Scientist
Elvira Burger
Project Management
+49 761 270-36712
+49 761 270-73570
Heidi Fricker
Clinical Research Associate
+49 761 270 77390
+49 761 270 73570
Natalie Malenica
Study Nurse
+49 761 270 72140
+49 761 270 73570
Annika Vreden
Medical Doctorate Student
Dr. Inna Semenova
Clinical Research Associate
Marilena Meyer
Medical Doctorate Student
Tatja Dopatka
Project Assistant
+49 761 270 72290
+49 761 270 73570
Dr. med. Julia Wendler
Clinician Scientist
Simone Neumaier
Clinician Scientist
Sophia Dotterer
Monitoring
Daniela Hilbig
Clinician Scientist
Cora Steinheber
Study Nurse and Monitoring
+49 711 278-54720
+49 711 278-35649
Present and previous funding:
- Bundesministerium für Bildung und Forschung (BMBF)
- Else Kröner-Fresenius-Stiftung (EKFS)
- Medizinische Fakultät – Albert-Ludwigs-Universität Freiburg
Internal collaborations:
- PD Dr. Florian Scherer, Klinik für Innere Medizin I (coordination translational research program)
- Zentrum für Klinische Studien (ZKS) Freiburg
- Prof. Dr. Joachim Weis, CCCF, Selbsthilfeforschung
- Dr. Christiane Schmucker, Institut für Evidenz in der Medizin (für Cochrane Deutschland Stiftung)
- Abteilung Stereotaktische und Funktionelle Neurochirurgie
- Dr. Alexander Rau, Klinik für Neuroradiologie
External collaborations:
- Participating trial centers in Germany (n ~ 44)
- International Extranodal Lymphom Study Group (IELSG) with all international trial sites
- Dr. Kate Cwynarski (London, UK)
- Dr. Andres Ferreri (Milano, Italy)
- Prof. Dr. Christopher Fox (Nottingham, UK)
- Prof. Dr. Matthias Backenstraß, Institut für Klinische Psychologie, Klinikum Stuttgart
- Dr. Alexander Friedl, Geriatrisches Zentrum Stuttgart
- Dr. Elina Henkes, Abteilung für Neuroradiologie, Klinikum Stuttgart
- Prof. Dr. Martina Deckert, Institut für Neuropathologie, Universitätsklinikum Köln
- Prof. Dr. Falko Fend, Institut für Pathologie, Universitätsklinikum Tübingen
Original research
*equal contribution
-
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, Cwynarski K, Fox CP, Hoang-Xuan K, Malaise D, Ponzoni M, Schorb E, Soussain C, Specht L, Zucca E, Buske C, Jerkeman M, Dreyling M; EHA and ESMO Guidelines Committees.
Ann Oncol. 2024 (IF= 56.7) -
Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ferreri AJM, Illerhaus G, Doorduijn JK, Auer DP, Bromberg JEC, Calimeri T, Cwynarski K, Fox CP, Hoang-Xuan K, Malaise D, Ponzoni M, Schorb E, Soussain C, Specht L, Zucca E, Buske C, Jerkeman M, Dreyling M; EHA and ESMO Guidelines Committees.
Hemasphere. 2024 (IF= 12.1) -
Improved early outcome prediction by MRI-based 3D tumor volume assessment in patients with CNS lymphomas.
Lauer EM, Riegler E, Mutter JA, Alig SK, Bleul S, Kuehn J, Ranganathan L, Klingler C, Demerath T, Würtemberger U, Rau A, Weiß J, Eisenblaetter M, Bamberg F, Prinz M, Finke J, Duyster J, Illerhaus G, Diehn M, Alizadeh AA, Schorb E, Reinacher PC, Scherer F.
Neuro Oncol. 2024 (IF= 15.9) -
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial.
Schorb E, Isbell LK, Kerkhoff A, Mathas S, Braulke F, Egerer G, Röth A, Schliffke S, Borchmann P, Brunnberg U, Kroschinsky F, Möhle R, Rank A, Wellnitz D, Kasenda B, Pospiech L, Wendler J, Scherer F, Deckert M, Henkes E, von Gottberg P, Gmehlin D, Bakenstrass M, Jensch A, Burger-Martin E, Grishina O, Fricker H, Malenica N, Orbán A, Duyster J, Ihorst G, Finke J, Illerhaus G.
Lancet Haematol. 2024 (IF= 24.7) -
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients - the randomized phase III PRIMA-CNS trial.
Isbell LK, Uibeleisen R, Friedl A, Burger E, Dopatka T, Scherer F, Orban A, Lauer E, Malenica N, Semenova I, Vreden A, Valk E, Wendler J, Neumaier S, Fricker H, El Rabih AAH, Gloggengießer C, Hilbig D, Bleul S, Weis J, Gmehlin D, Backenstrass M, Wirtz S, Ihorst G, Finke J, Illerhaus G, Schorb E.
BMC Cancer. 2023 (IF= 3.8) -
Central nervous system lymphomas-Assessment and treatment and prevention of central nervous system relapse.
Ghione P, Lewis KL, Bobillo S, Nayak L, Schorb E, Nichelli L, Ng A, Savage KJ, McKay P, Nastoupil L, Soussain C, Cwynarski K.
Hematol Oncol. 2023 (IF= 3.3) -
Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
Mutter JA, Alig SK, Esfahani MS, Lauer EM, Mitschke J, Kurtz DM, Kühn J, Bleul S, Olsen M, Liu CL, Jin MC, Macaulay CW, Neidert N, Volk T, Eisenblaetter M, Rauer S, Heiland DH, Finke J, Duyster J, Wehrle J, Prinz M, Illerhaus G, Reinacher PC, Schorb E, Diehn M, Alizadeh AA, Scherer F.
J Clin Oncol. 2023 (IF= 45.3) -
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma.
Khwaja J, Kirkwood AA, Isbell LK, Steffanoni S, Goradia H, Pospiech L, Fail T, Nicholson E, Fletcher K, Linton KM, Parsons KE, Elmusharaf N, Eccersley L, Eyre TA, Chaganti S, Smith J, Thakrar N, Kutilina A, Calimeri T, Martinez-Calle N, El-Sharkawi D, Osborne W, Illerhaus G, Fox CP, Ferreri AJM, Schorb E, Cwynarski K.
Haematologica. 2023 (IF= 10.1) -
Patient-derived xenograft mouse models to investigate tropism to the central nervous system and retina of primary and secondary central nervous system lymphoma.
Isbell LK, Tschuch C, Doostkam S, Waldeck S, Andrieux G, Shoumariyeh K, Lenhard D, Schaefer HE, Reinacher PC, Bartsch I, Pantic M, Vinnakota JM, Kakkassery V, Schorb E, Scherer F, Frey AV, Boerries M, Illerhaus G, Duyster J, Schueler J, von Bubnoff N.
Neuropathol Appl Neurobiol. 2023 (IF= 5.0) -
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Rosée P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, Gørløv JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G; IELSG32 study investigators.
Leukemia. 2022 (IF= 11.4) -
Optimizing MATRix as remission induction in PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma.
Wendler J, Fox CP, Valk E, Steinheber C, Fricker H, Isbell LK, Neumaier S, OkosunJ, Scherer F, Ihorst G, Cwynarski K, Schorb E*, Illerhaus* (*shared last authorship).
BMC Cancer 2022 (IF= 3.8) -
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Wilson M , Eyre TA, Kirkwood AA , Wong Doo N , Soussain C, Choquet S , Martinez Calle N, Preston G, Ahearne M, Schorb E, Marie-Pierre M, Ku M , Rusconi C, Khwaja J, Narkhede M, Lewis K , Calimeri C, Durot E, Renaud L, Kiesbye Øvlisen A, McIlroy G, Ebsworth J, Elliot J, Santarsieri A, Ricard L , Shah N, Liu Q, Zayac AS , Vassallo F, Lebras L, Roulin L, Lombion, Manos K, Fernandez R , Hamad N, Lopez Garcia A, O'Mahony D, Gounder P, Forgeard N, Lees C , Agbetiafa K , Strüßmann T , Win Htut T, Clavert A , Scott H, Guidetti A, Barlow BR, Tchernonog E , Smith J , Miall F , Fox CP, Cheah CY, El Galaly TC , Ferreri AJM , Cwynarski K, McKay P.
Blood. 2022 (IF= 20.3) -
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.
Collins, G, Eyre TR, Schmitz-Rohmer D, Townsend W, Popat R, Giulino-Roth L, Fields P, Krasniqi F, Soussain C, Stathis A, Andjelkovic N, Cunningham D, Mandic D, Radulovic S, Tijanic I, Horowitz N, Kurtovic S, Schorb E, Dimitrijević S, Dreyling M, Schmidt C.
HemaSphere. 2021 (IF= 2.446) -
Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review
Schorb E, Isbell LK, Illerhaus G, Ihorst G, Meerpohl JJ, Grummich K, Nagavci B, Schmucker C.
Cancers (Basel). 2021 (IF= 6.575) -
Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
Montesinos-Rongen M, Brunn A, Tuchscherer A, Borchmann P, Schorb E, Kasenda B, Altmüller J, Illerhaus G, Ruge MI, Maarouf M, Büttner R, Hansmann ML, Hallek M, Prinz M, Siebert R, Deckert M.
J Mol Diagn. 2020 (IF= 5.568) - High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study.
Schorb E, Kasenda B, Ihorst G, Scherer F, Wendler J, Isbell L, Fricker H, Finke J, Illerhaus G
Blood Advances 2020
- Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
Lauer EM, Waterhouse M, Braig M, Mutter J, Bleul S, Duque-Afonso J, Duyster J, Marks R, Reinacher PC, Prinz M, Illerhaus G, Finke J, Schorb E, Scherer F.
Br J Haematol. 2020
- Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, Ninkovic S, Eyre TA, Cummin T, Smith J, Yallop D, De Marco B, Krampera M, Trefz S, Orsucci L, Fabbri A, Illerhaus G, Cwynarski K, Ferreri AJM
Br J Haematol. 2020
- Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
Schorb E, Finke J, Ihorst G, Kasenda B, Fricker H, Illerhaus G
BMC Cancer. 2019
- Rituximab in primary central nervous system lymphoma - A systematic review and meta-analysis.
Schmitt AM, Herbrand AK, Fox CP, Bakunina K, Bromberg JEC, Cwynarski K, Doorduijn JK, Ferreri AJM, Illerhaus G, Issa S, Schorb E, Zucca E, Hemkens LG, Schandelmaier S, Kasenda B.
Hematol Oncol. 2019
- The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.
Hottenrott T*, Schorb E*, Fritsch K, Dersch R, Berger B, Huzly D, Rauer S, Tebartz van Elst L, Endres D, Stich O.
J Neurol. 2018
- Hyper N-glycosylated SAMD14 and neurabin-I as driver CNS autoantigens of PCNSL.
Thurner L, Preuss KD, Bewarder M, Kemele M, Fadle N, Regitz E, Altmeyer S, Schormann C, Poeschel V, Ziepert M, Walter S, Roth P, Weller M, Szczepanowski M, Klapper W, Monoranu C, Rosenwald A, Möller P, Hartmann S, Hansmann ML, Mackensen A, Schäfer H, Schorb E, Illerhaus G, Buslei R, Bohle RM, Stilgenbauer S, Kim YJ, Pfreundschuh M.
Blood. 2018
- Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).
Lancet Haematol. 2017
- High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study.
Schorb E, Fox CP, Fritsch K, Isbell L, Neubauer A, Tzalavras A, Witherall R, Choquet S, Kuittinen O, De-Silva D, Cwynarski K, Houillier C, Hoang-Xuan K, Touitou V, Cassoux N, Marolleau JP, Tamburini J, Houot R, Delwail V, Illerhaus G, Soussain C, Kasenda B.
Bone Marrow Transplant. 2017
- High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.
Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G.
Leukemia. 2017
- High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).
Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Heß G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Röth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G.
Leukemia. 2017
- High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E, Finke J, Ferreri AJ, Ihorst G, Mikesch K, Kasenda B, Fritsch K, Fricker H, Burger E, Grishina O, Valk E, Zucca E, Illerhaus G.
BMC Cancer. 2016
- High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.
Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, Wolf HH, Hirt C, Stilgenbauer S, Binder M, Hau P, Edinger M, Frickhofen N, Bentz M, Möhle R, Röth A, Pfreundschuh M, von Baumgarten L, Deckert M, Hader C, Fricker H, Valk E, Schorb E, Fritsch K, Finke J.
Lancet Haematol. 2016
- Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG).
Lancet Haematol. 2016
- Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation.
Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, Elter T, von Bubnoff N, Dreyling M, Ringhoffer M, Krause SW, Derigs G, Klimm B, Niemann D, Fritsch K, Finke J, Illerhaus G.
Haematologica. 2013
- Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.
Doolittle ND, Korfel A, Lubow MA, Schorb E, Schlegel U, Rogowski S, Fu R, Dósa E, Illerhaus G, Kraemer DF, Muldoon LL, Calabrese P, Hedrick N, Tyson RM, Jahnke K, Maron LM, Butler RW, Neuwelt EA.
Neurology. 2013
- 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma.
Kasenda B, Haug V, Schorb E, Fritsch K, Finke J, Mix M, Hader C, Weber WA, Illerhaus G, Meyer PT.
J Nucl Med. 2013
- Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.
Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G.
Ann Oncol. 2012
- The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.
Kasenda B, Rehberg M, Thürmann P, Franzem M, Veelken H, Fritsch K, Schorb E, Finke J, Lebiedz D, Illerhaus G.
Ann Hematol. 2012
Case reports
- Primary CNS lymphoma-radiation-free salvage therapy by second autologous stem cell transplantation.
Kasenda B, Schorb E, Fritsch K, Hader C, Finke J, Illerhaus G.
Biol Blood Marrow Transplant. 2011
Reviews
- Aktuelle Therapiestandards primärer ZNS Lymphome
Schorb E, Illerhaus G, Finke J
Dtsch Med Wochenschr 2019 - Novel agents for primary central nervous system lymphoma (PCNSL) - evidence and perspectives - Invited review.
Illerhaus G, Schorb E, Kasenda B
Blood. 2018 - Advances in treatment of elderly primary central nervous system lymphoma
Nicolas Martinez-Calle, Lisa K. Isbell, Kate Cwynarski, Elisabeth Schorb
==> onlinelibrary.wiley.com/doi/10.1111/bjh.17799 - Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review
Elisabeth Schorb, Lisa Kristina Isbell, Gerald Illerhaus, Gabriele Ihorst, Joerg J Meerpohl, Kathrin Grummich, Blin Nagavci, Christine Schmucker
==> pubmed.ncbi.nlm.nih.gov/34503078/
Books
- Das Primäre ZNS-Lymphom
Illerhaus G, Kasenda B, Schorb E
UNI-MED Verlag AG; Auflage 1, 2019
Abstracts
- Vreden A., I., L., Ihorst, G., Kerkhoff, A., Fricker H., Malenica N., Finke J., Illerhaus G., Schorb E.,
Deutsche, Österreichische und Schweizerische Gesellschaften für Hämatologie und Medizinische Onkologie.
Oncol Res Treat 2021. 44(I–III).
==> https://www.karger.com/Journal/Issue/280769
- Advanced Clinican Scientist Award, Medizinische Fakultät Freiburg
- Clinical Research Training in Hematology Award, European Hematology Association (EHA)
- International PCNSL Cooperative Group Travel Scholarship Award
Contact Cooperative Study Group
Primary Central Nervous System Lymphoma (PCNSL)
PD Dr. Elisabeth Schorb
Principal Investigator
Sekretariat: Dr.rer.nat. Peggy Engelhard
+49 761 270 35360
kontakt.studiengruppe.zns-nhl@uniklinik-freiburg.de
peggy.engelhard@uniklinik-freiburg.de
Universitätsklinikum Freiburg
Klinik für Innere Medizin I
Hugstetter Straße 55
D-79106 Freiburg
Elvira Burger
Project Management
+49 761 270-36712
+49 761 270-73570
elvira.burger@uniklinik-freiburg.de
Universitätsklinikum Freiburg
Klinik für Innere Medizin I
Hugstetter Straße 55
D-79106 Freiburg